Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice

Gene Therapy

Volumn 14, Issue 6, 2007, Pages 503-513

  Lyons, J A ^a   Sheahan, B J ^a   Galbraith, S E ^a,b   Mehra, R ^c   Atkins, G J ^b   Fleeton, M N ^b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; INTERLEUKIN 12; INTERLEUKIN 4; VASCULOTROPIN RECEPTOR 2; VIRUS VECTOR;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; COLON CARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DENSITY; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; HEMATOPOIESIS; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; LUNG METASTASIS; METASTASIS INHIBITION; MICROVASCULATURE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEMLIKI FOREST ALPHAVIRUS; SURVIVAL RATE; SURVIVAL TIME; TUMOR IMMUNITY; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM; VIRUS PARTICLE; VIRUS RECOMBINANT;

ANIMALS; AUTOANTIBODIES; COLONIC NEOPLASMS; FEMALE; GENE THERAPY; GENETIC VECTORS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-4; LYMPHATIC METASTASIS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SEMLIKI FOREST VIRUS; TRANSDUCTION, GENETIC; VACCINATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MURINAE; MUS; SEMLIKI FOREST VIRUS;

EID: 33847789011     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302889     Document Type: Article

References (40)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-18.
2. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-974.
3. Augustin HG. Antiangiogenic tumour therapy: Will it work? Trends Pharmacol Sci 1998; 19: 216-222.
4. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404-407.
5. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-153.
6. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E et al. Genes expressed in human tumor endothelium. Science 2000; 289: 1197-1202.
7. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001; 61: 6649-6655.
8. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001; 7: 987-989.
9. Mauceri HJ, Hanna NN, Beckett MA, Gorski DH, Staba MJ, Stellato KA et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998; 394: 287-291.
10. Folkman J, D'Amore PA. Blood vessel formation: What is its molecular basis? Cell 1996; 87: 1153-1155.
11. Ferrara N. VEGF: An update on biological and therapeutic aspects. Curr Opin Biotechnol 2000; 11: 617-624.
12. Taraboletti G, Margosio B. Antiangiogenic and antivascular therapy for cancer. Curr Opin Pharmacol 2001; 1: 378-384.
13. Ochsenbein AF, Sierro S, Odermatt B, Pericin M, Karrer U, Hermans J et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 2001; 411: 1058-1064.
14. Okaji Y, Tsuno NH, Saito S, Yoneyama S, Tanaka M, Nagawa H et al. Vaccines targeting tumour angiogenesis-a novel strategy for cancer immunotherapy. Eur J Surg Oncol 2006 (E-pub ahead of print).
15. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.
16. Liu JY, Wei YQ, Yang L, Zhao X, Tian L, Hou JM et al. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 2003; 102: 1815-1823.
17. Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M et al. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res 2005; 65: 4939-4946.
18. Li Y, Wang MN, Li H, King KD, Bassi R, Sun H et al. Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 2002; 195: 1575-1584.
19. Nair S, Boczkowski D, Moeller B, Dewhirst M, Vieweg J, Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 2003; 102: 964-971.
20. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G et al. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002; 8: 1369-1375.
21. Zhou H, Luo Y, Mizutani M, Mizutani N, Reisfeld RA, Xiang R. T cell-mediated suppression of angiogenesis results in tumor protective immunity. Blood 2005; 106: 2026-2032.
22. Smerdou C, Liljestrom P. Two-helper RNA system for production of recombinant Semliki forest virus particles. J Virol 1999; 73: 1092-1098.
23. Berglund P, Sjoberg M, Garoff H, Atkins GJ, Sheahan BJ, Liljestrom P. Semliki Forest virus expression system: Production of conditionally infectious recombinant particles. Biotechnology (New York) 1993; 11: 916-920.
24. Berglund P, Fleeton MN, Smerdou C, Liljestrom P. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 1999; 17: 497-507.
25. Fleeton MN, Sheahan BJ, Gould EA, Atkins GJ, Liljestrom P. Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge. J Gen Virol 1999; 80: 1189-1198.
26. Fleeton MN, Chen M, Berglund P, Rhodes G, Parker SE, Murphy M et al. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis 2001; 183: 1395-1398.
27. Jerusalmi A, Morris-Downes MM, Sheahan BJ, Atkins GJ. Effect of intranasal administration of Semliki Forest virus recombinant particles expressing reporter and cytokine genes on the progression of experimental autoimmune encephalomyelitis. Mol Ther 2003; 8: 886-894.
28. Chikkanna-Gowda CP, Sheahan BJ, Fleeton MN, Atkins GJ. Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Therapy 2005; 12: 1253-1263.
29. Rodriguez-Madoz JR, Prieto J, Smerdou C. Semliki forest virus vectors engineered to express higher IL-12 levels induce efficient elimination of murine colon adenocarcinomas. Mol Ther 2005; 12: 153-163.
30. Colmenero P, Chen M, Castanos-Velez E, Liljestrom P, Jondal M. Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. Int J Cancer 2002; 98: 554-560.
31. Colmenero P, Liljestrom P, Jondal M. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene. Gene Therapy 1999; 6: 1728-1733.
32. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002; 2: 933-944.
33. Shalaby F, Ho J, Stanford WL, Fischer KD, Schuh AC, Schwartz L et al. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 1997; 89: 981-990.
34. Pan J, Heiser A, Marget M, Steinmann J, Kabelitz D. Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccination. Gene Therapy 2005; 12: 742-750.
35. Feng KK, Zhao Y, Qiu H, Liu JX, Chen J. Combined therapy with flk1-based DNA vaccine and interleukin-12 results in enhanced antiangiogenic and antitumor effects. Cancer Lett 2005; 221: 41-47.
36. Chen Y, Hu D, Eling DJ, Robbins J, Kipps TJ. DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors. Cancer Res 1998; 58: 1965-1971.
37. Chen M, Hu KF, Rozell B, Orvell C, Morein B, Liljestrom P. Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J Immunol 2002; 169: 3208-3216.
38. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54: 721-728.
39. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y et al. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med 2000; 6: 1160-1166.
40. Smyth JW, Fleeton MN, Sheahan BJ, Atkins GJ. Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector. Gene Therapy 2005; 12: 147-159.